Literature DB >> 11467373

Relationship between IFN-gamma and skin test responsiveness to Mycobacterium tuberculosis PPD in healthy, non-BCG-vaccinated young adults in Northern Malawi.

G F Black1, D K Warndorff, S Floyd, R E Weir, J M Blackwell, L Bliss, L Sichali, L Mwaungulu, S Chaguluka, E Jarman, B Ngwira, H M Dockrell.   

Abstract

SETTING: Rural northern Malawi, where vaccination with BCG Glaxo (1077) provides protection against leprosy but not against pulmonary tuberculosis.
OBJECTIVE: To evaluate the patterns of responsiveness to purified protein derivative of Mycobacterium tuberculosis (PPD) in terms of delayed type hypersensitivity (DTH) and interferon-gamma (IFN-gamma) production.
DESIGN: IFN-gamma was measured in 6 day whole blood cultures diluted 1 in 10, stimulated with PPD RT48, and the results compared to the DTH response to PPD RT23. A total of 633 individuals aged 12 to 28 years, without prior BCG vaccination, were recruited.
RESULTS: Overall, 63% of subjects made a positive IFN-gamma response (defined as >62 pg/ml), and 37% gave a DTH induration of >5 mm. A strong correlation between skin test and IFN-gamma responses was observed, although with interesting exceptions: 13/270 individuals with zero DTH showed IFN-gamma responses >500 pg/ml, and 7/53 individuals with >10 mm induration showed IFN-gamma responses < or = 62 pg/ml. The prevalence of skin test responsiveness increased with age, and was higher among older males than females; age-sex patterns were less clear for IFN-gamma production.
CONCLUSION: The 6 day IFN-gamma response to PPD correlates well with Mantoux skin test induration. The discordant individuals may represent important subsets in terms of protective immunity and risk of clinical tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11467373

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  34 in total

1.  Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing.

Authors:  S A Sharpe; H McShane; M J Dennis; R J Basaraba; F Gleeson; G Hall; A McIntyre; K Gooch; S Clark; N E R Beveridge; E Nuth; A White; A Marriott; S Dowall; A V S Hill; A Williams; P D Marsh
Journal:  Clin Vaccine Immunol       Date:  2010-06-09

2.  Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease.

Authors:  Lerisa Govender; Brian Abel; E Jane Hughes; Thomas J Scriba; Benjamin M N Kagina; Marwou de Kock; Gerhard Walzl; Gillian Black; Ida Rosenkrands; Gregory D Hussey; Hassan Mahomed; Peter Andersen; Willem A Hanekom
Journal:  Vaccine       Date:  2010-10-23       Impact factor: 3.641

Review 3.  The potential of Mycobacterium to protect against allergy and asthma.

Authors:  Charles C Obihara; Jan L L Kimpen; Nulda Beyers
Journal:  Curr Allergy Asthma Rep       Date:  2007-06       Impact factor: 4.806

Review 4.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

5.  Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection.

Authors:  S M B Jeronimo; A K B Holst; S E Jamieson; R Francis; D R A Martins; F L Bezerra; N A Ettinger; E T Nascimento; G R Monteiro; H G Lacerda; E N Miller; H J Cordell; P Duggal; T H Beaty; J M Blackwell; M E Wilson
Journal:  Genes Immun       Date:  2007-08-23       Impact factor: 2.676

6.  What has Karonga taught us? Tuberculosis studied over three decades.

Authors:  A C Crampin; J R Glynn; P E M Fine
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

7.  Mycobacterial purified protein derivatives stimulate innate immunity: Malawians show enhanced tumor necrosis factor alpha, interleukin-1beta (IL-1beta), and IL-10 responses compared to those of adolescents in the United Kingdom.

Authors:  Rosemary E Weir; Gillian F Black; Hazel M Dockrell; Sian Floyd; Paul E M Fine; Steven D Chaguluka; Sally Stenson; Elizabeth King; Bernadette Nazareth; David K Warndorff; Bagrey Ngwira; Amelia C Crampin; Lorren Mwaungulu; Lifted Sichali; Elizabeth Jarman; Linda Donovan; Jenefer M Blackwell
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

Review 8.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

9.  Evaluation of the diagnostic utility of a whole-blood interferon-gamma assay for determining the risk of exposure to Mycobacterium tuberculosis in Bacille Calmette-Guerin (BCG)-vaccinated individuals.

Authors:  Seok-Yong Eum; Ye-Jin Lee; Hyun-Kyung Kwak; Jin-Hong Min; Soo-Hee Hwang; Laura E Via; Clifton E Barry; Sang-Nae Cho
Journal:  Diagn Microbiol Infect Dis       Date:  2008-03-04       Impact factor: 2.803

10.  Biomarker changes associated with Tuberculin Skin Test (TST) conversion: a two-year longitudinal follow-up study in exposed household contacts.

Authors:  Rabia Hussain; Najeeha Talat; Firdaus Shahid; Ghaffar Dawood
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.